Hepatitis C Virus Nucleotide Analog NS5B Polymerase Inhibitor
5 drugs across 2 manufacturers|1 Generic,4 Brand
The Hepatitis C Virus Nucleotide Analog NS5B Polymerase Inhibitor class contains 5 NDCs from 2 manufacturers (1 generic, 4 brand), at an average NADAC of $815.47 per unit. Every drug, manufacturer, and price in this FDA-defined pharmacologic class is listed below.
Total Drugs
5
1G / 4B
Manufacturers
2
Avg $815.4748/unit
Avg 7d Change
+0.01%
Across 2 drugs with changes
7d Activity
of 5 total drugs
Class Price Trend
Monthly average NADAC price per unit, split by generic and brand
Manufacturer Breakdown
2 manufacturers producing drugs in this therapeutic class
| Drug ↕ | Price | 7d Change ↕ |
|---|---|---|
HARVONI 90-400 MG TABLET LEDIPASVIR and SOFOSBUVIR | $1098.9375 per EA | — |
SOVALDI 400 MG TABLET SOFOSBUVIR | $975.3000 per EA | — |
EPCLUSA 400 MG-100 MG TABLET Velpatasvir and Sofosbuvir | $866.3988 per EA | +0.05% |
VOSEVI 400-100-100 MG TABLET SOFOSBUVIR, VELPATASVIR, and VOXILAPREVIR | $858.6884 per EA | — |
SOFOSBUVIR-VELPATASVIR 400-100 Velpatasvir and Sofosbuvir | $278.0492 per EA | -0.04% |
Frequently Asked Questions
How many drugs are in the Hepatitis C Virus Nucleotide Analog NS5B Polymerase Inhibitor class?
The Hepatitis C Virus Nucleotide Analog NS5B Polymerase Inhibitor class contains 5 NDCs from 2 manufacturers — 1 generic and 4 brand products.
What is the average price of Hepatitis C Virus Nucleotide Analog NS5B Polymerase Inhibitor drugs?
The average NADAC for the Hepatitis C Virus Nucleotide Analog NS5B Polymerase Inhibitor class is $815.4748 per unit across 5 NDCs.
Is generic cheaper than brand in the Hepatitis C Virus Nucleotide Analog NS5B Polymerase Inhibitor class?
Among products priced per EA, the average generic NADAC in this class is $278.0492, versus $949.8312 for brand — brand products average about 3.4× the generic price.
Which manufacturers make Hepatitis C Virus Nucleotide Analog NS5B Polymerase Inhibitor drugs?
2 manufacturers make drugs in the Hepatitis C Virus Nucleotide Analog NS5B Polymerase Inhibitor class. Ranked by number of NDCs, the largest are Gilead Sciences, Inc. (4), Asegua Therapeutics LLC (1).
How has Hepatitis C Virus Nucleotide Analog NS5B Polymerase Inhibitor pricing changed recently?
Over the past 7 days, 1 NDC in this class rose and 1 fell, with a class-wide average change of +0.0%.